Adagio medical holdings, inc. receives fda breakthrough device designation for the vclastm cryoablation system

Laguna hills, calif.--(business wire)--adagio medical holdings, inc. (nasdaq: adgm) (“adagio” or “the company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has received breakthrough device designation from the u.s. food and drug administration (“fda”) for its vclastm cryoablation system for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (“vt”) in patients with ischemic or non.
ADGM Ratings Summary
ADGM Quant Ranking